Teva Pharmaceutical Industries Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard D. Francis
- Full Time Employees
- 32,008
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 124 Dvora Hanevi’a Street Tel Aviv TA Israel 6944020
- IPO Date
- Feb 16, 1982
- CIK
- 0000818686
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited, an Israeli multinational pharmaceutical company founded in 1901 and headquartered in Petah Tikva, Israel, develops, manufactures, markets and distributes generic medicines, innovative branded drugs, biopharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products worldwide across more than 60 countries with manufacturing facilities in Israel, North America, Europe, Australia and South America; core generic offerings span various dosage forms including tablets, capsules, ointments, creams, liquids, injectables and inhalants for therapeutic areas such as pain management, cardiovascular diseases, infectious diseases, central nervous system disorders, respiratory conditions, oncology and generics leadership in complex products; key innovative medicines include AUSTEDO (deutetrabenazine) for chorea in Huntington's disease and tardive dyskinesia, AJOVY (fremanezumab) for migraine prevention, UZEDY for schizophrenia, Copaxone for multiple sclerosis and a pipeline featuring olanzapine LAI, duvakitug for inflammatory bowel disease, DARI asthma inhaler, emrusolmin and TEV-56278 (anti-PD1-IL2 ATTENUKINE) for oncology. The company operates in segments including generics and biosimilars targeting healthcare providers, pharmacies and hospitals globally, with a focus on neuroscience, immunology, respiratory diseases and pain management customer bases. Teva advances its Pivot to Growth strategy, launched in 2023 and accelerated in 2025, to build a greater than $5 billion innovative medicines franchise by 2030 through robust late-stage pipeline execution, 25 to 27 biosimilar launches by 2027 including eculizumab-aagh with Samsung Bioepis and PONLIMSI/DEGEVMA denosumab biosimilars approved in Europe; recent strategic partnerships encompass a June 2025 collaboration with Fosun Pharma for TEV-56278 development in Asia, a prior alliance with Sanofi for TEV-574 anti-TL1A in inflammatory bowel disease, and the November 2025 launch of Teva Rise open innovation platform for AI, digital health and manufacturing advancements; ongoing efforts include divestiture of its API business TAPI announced in 2024, eleven consecutive quarters of revenue growth as of Q3 2025 driven by 33% innovative portfolio increase in local currency, reaffirmed 2027 targets of 30% operating profit margin, over $2.7 billion free cash flow and $2.5 billion Estero revenues with peak sales exceeding $3 billion, alongside credit upgrades reflecting debt reduction and operational enhancements.
Company News
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
Teva Releases Q3 2026 Aide Memoire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
Teva Pharmaceutical Industries (NYSE:TEVA) Insider Brian Savage Sells 7,342 Shares of Stock
Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 367,600 Shares of Stock
Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Most Active Options Report: FPS, TEVA, AFL
Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars
Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript